YORKVILLE ACQUI. A O.N.

Rein Therapeutics has terminated its Pre-Paid Advance Agreement and Standby Equity Purchase Agreement with Yorkville; according to an SEC filing, the company will incur no penalties or fees. The company did not sell any common stock under the equity purchase agreement and had previously received up to $3 million in advance payments; a third advance payment of $1 million was also secured. Separately, Rein reported positive data for LTI-03 against idiopathic pulmonary fibrosis, the FDA lifted the clinical hold on the Phase 2 study, and recruitment is expected to start in late 2025/early 2026; Brookline Capital Markets upgraded the stock to "buy." » More on de.investing.com